Free Trial
NASDAQ:ADTX

Aditxt Q1 2025 Earnings Report

Aditxt logo
$0.0032 0.00 (-5.88%)
As of 10/2/2026 03:58 PM Eastern

Aditxt EPS Results

Actual EPS
-$198,192.96
Consensus EPS
-$644,371,200.00
Beat/Miss
Beat by +$644,173,007.04
One Year Ago EPS
N/A

Aditxt Revenue Results

Actual Revenue
$0.00 million
Expected Revenue
$0.43 million
Beat/Miss
Missed by -$424.00 thousand
YoY Revenue Growth
N/A

Aditxt Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Aditxt's next earnings date is estimated for Wednesday, December 2, 2026, based on past reporting schedules.

Conference Call Resources

Aditxt Earnings Headlines

Merck & Co., Inc. (NYSE:MRK) vs. Aditxt (NASDAQ:ADTX) Head to Head Analysis
Aditxt Faces Nasdaq Delisting, Moves Fully to OTC
The case for $20,000 gold before year end
President Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and America's $40 trillion national debt to a potential surge in gold prices, with some forecasts pointing to $10,000 or even $20,000 gold. Dr. David Eifrig, a 40-year market veteran and former Goldman Sachs Vice President, says an unusual plan involving Trump and two other top officials could fuel the biggest gold bull run in decades. Eifrig has shared his top gold pick tied to this developing story.tc pixel
Aditxt Stock Dividends | NASDAQ:ADTX | Benzinga
See More Aditxt Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aditxt? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aditxt and other key companies, straight to your email.

About Aditxt

Aditxt (NASDAQ:ADTX) is a biotechnology company focused on technologies designed to monitor and reprogram the immune system. The company’s work is aimed at supporting precision medicine by providing detailed information about how an individual’s immune system responds to diseases, vaccines and other biological stimuli.

Aditxt’s core technology platform, AditxtScore, is designed to analyze multiple immune responses simultaneously. Potential applications include infectious disease testing, vaccine-response monitoring, autoimmune disease research and other areas where immune-system profiling may support diagnosis, treatment development or clinical decision-making.

Founded in 2017, Aditxt is headquartered in Mountain View, California. The company has also pursued additional life-sciences initiatives and collaborations intended to expand the use of immune-monitoring and diagnostic technologies. Amro Albanna, a co-founder of the company, has served as its chief executive officer.

View Aditxt Profile